➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Harvard Business School
Baxter
Mallinckrodt
Medtronic

Last Updated: April 20, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Reparixin

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Reparixin?

Reparixin is an investigational drug.

There have been 9 clinical trials for Reparixin. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2012.

The most common disease conditions in clinical trials are Breast Neoplasms, Diabetes Mellitus, Type 1, and Diabetes Mellitus. The leading clinical trial sponsors are Dompé Farmaceutici S.p.A, PRA Health Sciences, and [disabled in preview].

There are eighty-two US patents protecting this investigational drug and seven hundred and seventy-four international patents.

Recent Clinical Trials for Reparixin
TitleSponsorPhase
Reparixin in COVID-19 Pneumonia - Multicentre Study on the Efficacy and SafetyDompé Farmaceutici S.p.APhase 2/Phase 3
A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast CancerPRA Health SciencesPhase 2
A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast CancerDompé Farmaceutici S.p.APhase 2

See all Reparixin clinical trials

Clinical Trial Summary for Reparixin

Top disease conditions for Reparixin
Top clinical trial sponsors for Reparixin

See all Reparixin clinical trials

US Patents for Reparixin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Reparixin   Start Trial Heterocyclic compound Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
Reparixin   Start Trial Heterocyclic compound Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
Reparixin   Start Trial Combination therapy DIMERIX BIOSCIENCE PTY LTD. (Victoria, AU)   Start Trial
Reparixin   Start Trial Heterocyclic compound Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
Reparixin   Start Trial Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders OTONOMY, INC. (San Diego, CA) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA)   Start Trial
Reparixin   Start Trial Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
Reparixin   Start Trial Controlled release dosage form TRIASTEK, INC. (Nanjing, CN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Reparixin

Drugname Country Document Number Estimated Expiration Related US Patent
Reparixin Canada CA2961033 2034-09-11   Start Trial
Reparixin European Patent Office EP3192791 2034-09-11   Start Trial
Reparixin Japan JPWO2016039408 2034-09-11   Start Trial
Reparixin World Intellectual Property Organization (WIPO) WO2016039408 2034-09-11   Start Trial
Reparixin Argentina AR098909 2033-07-03   Start Trial
Reparixin European Patent Office EP3018126 2033-07-03   Start Trial
Reparixin Japan JP6427491 2033-07-03   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Harvard Business School
Baxter
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.